PD-1和PD-L1抑制剂在中晚期肝细胞癌中的应用及展望

Application and prospect of PD-1 or PD-L1 inhibitor in advanced hepatocellular carcinoma

肝细胞癌(HCC)是临床上常见的消化系统恶性肿瘤。近年来,免疫治疗的提出和发展在全球掀起一股抗癌热潮,特别是程序性死亡受体1(PD-1)和程序性死亡受体-配体1(PD-L1)抑制剂,已经应用于多种肿瘤疾病并取得较好的效果。但PD-1和PD-L1抑制剂在HCC中的应用多停留在临床试验阶段,部分临床试验在中晚期HCC及术后复发的患者中已取得不错的效果。更多的研究结果表明,PD-1和PD-L1抑制剂联合射频、放化疗、分子靶向药物等更能使患者获益。

Hepatocellular carcinoma(HCC)is one of the most common malignant tumors of the digestive system in the clinic.In recent years,the proposal and development of immunotherapy have set off a worldwide anticancer upsurge.In particular,programmed death receptor 1(PD-1)and programmed death receptor ligand 1(PD-L1)inhibitor have been used in a wide variety of tumor diseases and achieved good curative effect.However,the application of PD-1 or PD-L1 inhibitors in HCC is mostly still at the stage of clinical trials,and some clinical trials have shown gratifying results in patients with advanced HCC and postoperative recurrence.More studies have shown that PD-1 or PD-L1 inhibitors combined with radiofrequency,chemoradiotherapy,and molecular targeted drugs can bring greater benefits to patients.